Stemline rallies after outlining results from additional vaccine study


Stemline Therapeutics (STML +11.6%) enjoys a strong session after announcing late Friday evening that the results of a clinical trial of SL-701 in low-grade glioma were being presented at a Meeting of the World Federation of Neuro-Oncology.

The company says an abstract shows the vaccine is "well-tolerated and induced specific and sustained immune responses against its brain tumor targets."

Additionally, STML says the results show "patients with a high magnitude of immunologic responsiveness experienced prolonged progression free survival." (PR)

Comments (1)
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
     
    Another brilliancy from your HELPFUL INTERNET FRIENDS at SeekingBETA!!!

     

    FOLLOW the winner! Buy HIGH! Sell LOW!!

     

    This was GAME-CHANGING news! The stock is giong UP! Better BUY BUY BUY BUY BUY!!!

     

    Oops, down 15 percent! In a day! Sorry!!

     

    This site is becoming a great fade.
    26 Nov 2013, 03:40 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs